# A Phase 1 Dose Escalation and Expansion Study of AK117

> **NCT04728334** · PHASE1 · COMPLETED · sponsor: **Akeso** · enrollment: 49 (actual)

## Conditions studied

- Neoplasms Malignant

## Interventions

- **DRUG:** AK117

## Key facts

- **NCT ID:** NCT04728334
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-23
- **Primary completion:** 2022-01-25
- **Final completion:** 2023-05-12
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04728334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04728334, "A Phase 1 Dose Escalation and Expansion Study of AK117". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04728334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*